Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response.
Tabs: Avoid concomitant strong CYP3A inhibitors or P-gp inhibitors. Concomitant with moderate CYP3A inhibitors or P-gp inhibitors; monitor. Concomitant with sensitive CYP3A substrates (eg ...
Your body clears Xanax through a pathway known as cytochrome P450 3A (CYP3A). Medications that inhibit CYP3A4 make it harder for your body to break down Xanax, which increases your risk of overdosing.
Clarithromycin 125mg/5mL, 250mg/5mL; granules for oral susp; fruit-punch flavor. Pharyngitis/tonsillitis: 250mg every 12hrs for 10 days. Bronchitis: 250mg–500mg ...
Because CYP isoenzymes metabolize a large number of structurally diverse drugs and chemicals, most of the variant genotypes of the CYP2D6, CYP2C9, CYP2C19, and CYP3A families have been identified ...
老年人由于身体机能的衰退以及慢性疾病的困扰,需要长期服用药物来控制疾病。心血管类药物则是老年人最常服用的一大类药。然而容易被忽略的是,在日常的饮食中,食物也有可能对药物产生影响,可以增强药效,也可能降低药效,甚至会引起不良反应。本文总结了不同的食物成 ...
CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA ...
Avoid coadministration of GAVRETO with strong or moderate CYP3A inhibitors, P-gp inhibitors, or combined P-gp and strong or moderate CYP3A inhibitors. If coadministration cannot be avoided ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...
决奈达隆的商品名为Multaq ,是赛诺菲安万特公司开发的III 类抗心律失常药物。该药物于 2009 年 7 月获美国食品药品管理局 (FDA)批准。除了用于治疗心律失常外,它还被推荐作为胺碘酮的替代品,用于治疗心房颤动和心房扑动,适用于心脏已恢复正常节律或接受药物治疗或电击治疗,即直流电复律 (DCCV) 以维持正常节律的患者。
2023年10月26日,首个完整的HIV-1长效注射治疗方案:万凯锐 (卡替拉韦)和瑞卡必 (利匹韦林),获中国国家药品监督管理局 (NMPA) 批准。该方案每两个月注射一次,不用与口服 ...
瑞普替尼(Repotrectinib),商品名Augtyro,是一种新型的口服、小分子、多靶点的酪氨酸激酶抑制剂(TKI),主要用于治疗携带特定基因变异的晚期实体瘤,尤其是那些对现有治疗手段不再响应的患者。瑞普替尼的设计目标是克服由ALK(anaplastic lymphoma kinase)、ROS1(c-ros oncogene 1)和NTRK(neurotrophic tyrosine re ...